Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.33 |
| ▸ | JAK1 | P23458 | 4/20 | 0.33 |
| ▸ | TYK2 | P29597 | 4/20 | 0.33 |
| ▸ | JAK3 | P52333 | 4/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12958595 | 0.90 | CYP1A2 (0.41) | JAK2JAK1TYK2JAK3CYP1A2 | |
| SCHEMBL12960044 | 0.87 | CYP1A2 (0.41) | JAK2JAK1TYK2JAK3CYP1A2 | |
| SCHEMBL12959268 | 0.86 | JAK2 (0.34) | JAK2JAK1TYK2JAK3CYP1A2 | |
| SCHEMBL12958989 | 0.78 | PRKCI (0.43) | CYP1A2TSHRCASP1CASP7HSD17B10 | |
| SCHEMBL12959386 | 0.72 | MEN1 (0.52) | CYP1A2CASP1CASP7HSD17B10 | |
| SCHEMBL12959278 | 0.70 | JAK2 (0.40) | JAK2JAK1TYK2JAK3CYP1A2 | |
| SCHEMBL12959293 | 0.70 | MAPT (0.43) | JAK2JAK1TYK2JAK3CYP1A2 | |
| SCHEMBL12287021 | 0.70 | ADRA1D (0.45) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL13496361 | 0.67 | HDAC1 (0.41) | JAK2JAK1TYK2JAK3TSHR | |
| SCHEMBL12959357 | 0.67 | BCHE (0.39) | JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011008247-A1 | FLAVIN DERIVATIVES | BIORELIX, INC. (US) | 2011-01-20 | — | — | WO | disclosed |